

Manisha Juthani, MD Commissioner



Ned Lamont Governor Susan Bysiewicz Lt. Governor

Immunization Program

TO: All Connecticut Vaccine Program (CVP) Providers

FROM: Mick Bolduc Mich Carlot

Vaccine Coordinator, Connecticut Immunization Program

DATE: February 7, 2023

SUBJECT: Change in Rotarix Formulation

The purpose of this communication is to notify you of a change in the Rotarix formulation available through the Connecticut Vaccine Program (CVP).

Beginning March 1, 2023 the CVP will be providing a new formulation (NDC # 58160-0740-21) for Glaxo SmithKline's Rotarix vaccine. The new formulation will require no reconstitution and is the same schedule and number of doses as the current reconstituted formulation of Rotarix. More information about the new formulation can be found here: Homepage | ROTARIX (Rotavirus Vaccine, Live, Oral) for HCPs (rotarixhcp.com). Providers currently using Rotarix need to use up their existing supply of NDC # 58160-0854-52 before switching over to the new formulation to avoid any vaccine wastage.

As always if you have any questions, please feel free to contact me at (860) 509-7929.



